JYQ-88 is a potent, selective and covalent PARK7 inhibitor with IC50 of 0.13 uM in DiFMUAc assays, 100-fold selectivity over UCHL1 (PARK5, IC50=11.1 uM), covalently modifies the active site Cys106.

K786-4469 is a small molecule inhibitor of anoctamin 1 (ANO1), suppresses cancer metastasis in vitro and in vivo.

Kakeimide is a potent GH3 inhibitor that selectively targets IAA-conjugating GH3 proteins at subnanomolar concentrations in vitro, shows auxin-like activity by inhibiting endogenous IAA catabolism.

Karyostatin 1AKaryostatin 1A is a small molecule inhibitor of importin beta with binding affinity (Kd=0.3 uM), selectively inhibits the importin α/β pathway.

KBP-066 is a potent, selective dual amylin and calcitonin receptor agonist induces an equally potent body weight loss across a broad dose range in obese rats.

KIO-100 (PP-001) is a novel potent, specific small molecule inhibitor of DHODH with IC50 of <4 nM, 150-fold higher potency than leflunomide (IC50 of 650 nM).

KL101 (KL 101) is a isoform-selective small molecule stabilizer of Cryptochrome 1 (CRY1).

A ruthenium complex anticancer agent that is useful for metastatic tumors and cis-platin resistant tumors.

A promising ruthenium anticancer compound that blocks angiogenesis, endothelial cell proliferation and migration stimulated by VEGF or NO donor agent.

KRP-6 is a potent and highly selective macrophage migration inhibitory factor (MIF) ketonase inhibitor with IC50 of 4.31 uM, significantly reduces MIF-induced neutrophil migration.

KS10076 is a metal chelator with potent anti-cancer cytotoxicity, destabilizes STAT3 by elevating ROS, shows remarkable cytotoxic efficacy in 100 cancer cell lines of different types with IC50 of <1 uM.

KVS0001 is a specific and bioavailable small molecule inhibitor of SMG1 kinase, disrupts nonsense mediated decay (NMD).

KZR-8445 (KZR8445) is a cyclic depsipeptide, client-selective Sec61 inhibitor with IC50 of 100 nM, targets the Sec61 translocon and selectively modulate Sec61-mediated protein biogenesis.

L6H21 is an orally active, potent and specific myeloid differentiation 2 (MD-2) inhibitor with binding KD value of 33.3 uM, blocks the formation of the LPS-TLR4/MD-2 complex.

LI-2242 is a potent pan-IP6K inhibitor with IC50 of with IC50 of 31, 42 and 8.1 nM for IP6K1, IP6K2 and IP6K3, respectively.

LP-403812 is a specific small molecule inhibitor of mammalian proline transporter (PROT), inhibits PROT-mediated proline uptake with IC50 of 0.1 uM on both recombinant human and mouse PROT.

Metablok (LSALT peptide) is a specific DPEP1-binding peptide and nonenzymatic dipeptidase-1 (DPEP-1) inhibitor.

A manufactured form of the thyroid hormone thyroxine (T4) that typically used to treat hypothyroidism.

LX-6171 is a small molecule proline transporter (SLC6A7) inhibitor with potential for treating cognitive and other disorders.

Macrocyclic peptide D4-2 is a macrocyclic peptide consisting of 15 amino acids that binds to the ectodomain of mouse SIRPα (Kd=10 nM, IgV-B6 SIRPα) and efficiently blocks CD47-SIRPα interaction in an allosteric manner (IC50=0.18 uM).

MASM7 is a small molecule activator of mitochondrial fusion via mitofusins (MFN1 and MFN2), concentration-responsively increases mitochondrial aspect ratio (Mito AR) in MEFs with EC50 of 75 nM, directly and specifically modulates MFN1/2 fusogenic activity

MCI-100 is a small molecule that displays greater potency than sulindac to protect RPE cells against oxidative damage, with lacked significant COX inhibitory activity, MCI-100 is more active than sulindac in protecting cells against oxidative damage.